Newport Laboratories Announces Agent Agreement
US - Newport Laboratories, Minnesota has agreed to become sales agent for Merial swine vaccines. It will promote the products through Newport’s veterinarian and swine integrator customer base and earn the rights to market and distribute vaccines including SwiVax™-MH and Mycoplasma hyopneumoniae bacterin in the United States.
30 November 2007
2 minute read
SwiVax-MH is the first and only USDA-approved swine vaccine for needle-free administration via transdermal technology through the DERMA-VAC™ NF Transdermal Vaccination System, also developed by the animals health company.
“This relationship as a perfect match for each company,” said Steve Parker, Director of Swine Marketing, Merial US Region.
Merial will retain all product shipping and customer billing responsibilities, and will contribute product technical support through a working relationship with Newport Laboratories. Newport will serve as MERIAL’s sales agent by contributing its sales and marketing capability, and its relationships with top veterinarians, pig producers and industry leaders.
Dr. Randy Simonson, GM/COO, Newport Laboratories said that the agreement leverages both companies’ strengths. "The use of these products and delivery technology, along with the support of our strong sales and technical field force, will enhance the profitability of US pork producers through solution-based animal health care offerings. We are excited about what this technology offers. We are continually searching for ways to enhance product performance against disease outbreaks,” he added.
“This relationship as a perfect match for each company,” said Steve Parker, Director of Swine Marketing, Merial US Region.
Merial will retain all product shipping and customer billing responsibilities, and will contribute product technical support through a working relationship with Newport Laboratories. Newport will serve as MERIAL’s sales agent by contributing its sales and marketing capability, and its relationships with top veterinarians, pig producers and industry leaders.
Dr. Randy Simonson, GM/COO, Newport Laboratories said that the agreement leverages both companies’ strengths. "The use of these products and delivery technology, along with the support of our strong sales and technical field force, will enhance the profitability of US pork producers through solution-based animal health care offerings. We are excited about what this technology offers. We are continually searching for ways to enhance product performance against disease outbreaks,” he added.
